Last Updated: 11 Sep 2024
Executive Summary
United Therapeutics Corporation (UTHR) is a biotechnology company with a strong focus on developing and commercializing products to address unmet medical needs for patients with chronic and life-threatening diseases. The company has a market capitalization of $15.24 billion and is headquartered in Silver Spring, Maryland. UTHR has a trailing price-to-earnings (PE) ratio of 15.74, a forward PE of 12.38, and a price-to-sales ratio of 5.82. The company's 52-week high is $366.08, and its 52-week low is $208.62.
Company Overview
United Therapeutics was founded in 1996 and has since become a leader in the development and commercialization of products for the treatment of pulmonary arterial hypertension (PAH). The company's primary product is Remodulin, a vasodilator used to treat PAH. UTHR also markets Tyvaso, a nebulized form of treprostinil, and Orenitram, an oral form of treprostinil.
Fundamental Analysis
United Therapeutics has a strong financial profile. The company's revenue has grown steadily in recent years, and its profit margins are healthy. UTHR's earnings per share (EPS) have also grown steadily, and the company is expected to continue to grow its EPS in the future.
Technical Analysis
United Therapeutics' stock price has been trending higher in recent months. The stock is currently trading above its 50-day and 200-day moving averages, and it has formed a bullish pennant pattern. This pattern suggests that the stock is likely to continue to move higher in the short term.
Short Term Outlook
United Therapeutics' stock price is expected to continue to move higher in the short term. The stock is currently trading at a discount to its analyst target price of $357.77, and it has a strong technical outlook. Investors should consider buying UTHR stock at current levels.
Long Term Outlook
United Therapeutics is a well-positioned company with a strong product pipeline. The company is expected to continue to grow its revenue and EPS in the long term. Investors should consider buying and holding UTHR stock for the long term.
Analyst Recommendations
United Therapeutics is rated "Strong Buy" by 6 analysts, "Buy" by 5 analysts, and "Hold" by 4 analysts. The consensus analyst target price for UTHR stock is $357.77.
